Antioxidant therapy: Current status and future prospects

Current Medicinal Chemistry

Volumn 18, Issue 25, 2011, Pages 3871-3888

  Firuzi, O ^a   Miri, R ^a   Tavakkoli, M ^a   Saso, L ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antioxidant; Clinical trial; Edaravone; Idebenone; Lipoic acid; N acetylcysteine; Polyphenolic; Therapy; Vitamin A; Vitamin C; Vitamin E

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; BAICALEIN; CATECHIN; CATENA; CURCUMIN; DAFLON; DAIDZEIN; DIOSMIN; FLAVOCOXID; FLAVONOID; GENISTEIN; GREEN TEA EXTRACT; HESPERIDIN; IDEBENONE; ISOFLAVONE; LEAGLON; LIMBREL; MONOXERUTIN; NITRONE DERIVATIVE; NORPHENAZONE; PENTOXIFYLLINE; PLACEBO; QUERCETIN; RESVERATROL; SILIBININ; SILYMARIN; THIOCTIC ACID; TROXERUTIN; UBIDECARENONE; UBIQUINONE; UNCLASSIFIED DRUG; VITAMIN;

ACETAMINOPHEN TOXICITY; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANAPHYLAXIS; BIPOLAR DISORDER; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC VEIN INSUFFICIENCY; CLINICAL RESEARCH; CONTRAST INDUCED NEPHROPATHY; COUGHING; CYSTIC FIBROSIS; DEGENERATIVE DISEASE; DEPRESSION; DIABETIC NEUROPATHY; DIET SUPPLEMENTATION; DRUG INTOXICATION; DRY EYE; DUCHENNE MUSCULAR DYSTROPHY; ENDOMETRIUM HYPERPLASIA; EPIDEMIOLOGICAL DATA; FIBROSING ALVEOLITIS; FRIEDREICH ATAXIA; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IN VITRO STUDY; JAPAN; LEG ULCER; LIVER DISEASE; MIGRAINE; MORTALITY; NEOPLASM; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; PARKINSON DISEASE; POSTOPERATIVE HEMORRHAGE; PREVENTIVE MEDICINE; PRIMARY PREVENTION; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; STROKE; TEA; UNSPECIFIED SIDE EFFECT;

EID: 80052244346     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711803414368     Document Type: Review

References (271)

1. Halliwell, B.; Gutteridge, J.M.C. Free Radicals in Biology and Medicine. 4 ed. Oxford University Press, USA, 2007.
2. Hensley, K.; Floyd, R.A., Reactive oxygen species and protein oxidation in aging: a look back, a look ahead.Arch Biochem Biophys, 2002, 397, (2), 377-383. (Pubitemid 34852306)
3. Paravicini, T.M.; Touyz, R.M., NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities.Diabetes Care, 2008, 31 Suppl 2, S170-180.
4. Vanhoutte, P.M., How We Learned to Say NO.Arterioscler Thromb Vasc Biol, 2009, 29, (8), 1156-1160.
5. Bedard, K.; Krause, K.H., The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology.Physiol Rev, 2007, 87, (1), 245-313. (Pubitemid 46209993)
6. Murphy, M.P., How mitochondria produce reactive oxygen species.Biochem J, 2009, 417, (1), 1-13.
7. Valko, M.; Rhodes, C.J.; Moncol, J.; Izakovic, M.; Mazur, M., Free radicals, metals and antioxidants in oxidative stress-induced cancer.Chem Biol Interact, 2006, 160, (1), 1-40. (Pubitemid 43227479)
8. Sies, H., Oxidative stress: oxidants and antioxidants.Exp Physiol, 1997, 82, (2), 291-295. (Pubitemid 27182306)
9. Nunomura, A.; Perry, G.; Aliev, G.; Hirai, K.; Takeda, A.; Balraj, E.K.; Jones, P.K.; Ghanbari, H.; Wataya, T.; Shimohama, S.; Chiba, S.; Atwood, C.S.; Petersen, R.B.; Smith, M.A., Oxidative damage is the earliest event in Alzheimer disease.J Neuropathol Exp Neurol, 2001, 60, (8), 759-767. (Pubitemid 32678256)
10. Perry, G.; Nunomura, A.; Hirai, K.; Zhu, X.; Perez, M.; Avila, J.; Castellani, R.J.; Atwood, C.S.; Aliev, G.; Sayre, L.M.; Takeda, A.; Smith, M.A., Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?Free Radic Biol Med, 2002, 33, (11), 1475-1479. (Pubitemid 35351590)
11. Seet, R.C.; Lee, C.Y.; Lim, E.C.; Tan, J.J.; Quek, A.M.; Chong, W.L.; Looi, W.F.; Huang, S.H.; Wang, H.; Chan, Y.H.; Halliwell, B., Oxidative damage in Parkinson disease: Measurement using accurate biomarkers.Free Radic Biol Med, 2010, 48, (4), 560-566.
12. Aliev, G.; Obrenovich, M.E.; Reddy, V.P.; Shenk, J.C.; Moreira, P.I.; Nunomura, A.; Zhu, X.; Smith, M.A.; Perry, G., Antioxidant therapy in Alzheimer's disease: theory and practice.Mini Rev Med Chem, 2008, 8, (13), 1395-1406.
13. Migliore, L.; Fontana, I.; Trippi, F.; Colognato, R.; Coppede, F.; Tognoni, G.; Nucciarone, B.; Siciliano, G., Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients.Neurobiol Aging, 2005, 26, (5), 567-573. (Pubitemid 40228745)
14. Simpson, E.P.; Henry, Y.K.; Henkel, J.S.; Smith, R.G.; Appel, S.H., Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden.Neurology, 2004, 62, (10), 1758-1765. (Pubitemid 38661731)
15. Fydrych, A.; Moir, R.D.; Huang, Y.; Shi, J.; Rogers, T.; Huang, X., Amyloid- targeted metal chelation, anti-oxidative stress, and anti-inflammations as potential alzheimer's therapies.Current Bioactive Compounds 2008, 4, (3), 140-149.
16. Beal, M.F., Mitochondria, oxidative damage, and inflammation in Parkinson's disease.Ann N Y Acad Sci, 2003, 991, 120-131. (Pubitemid 36793808)
17. Halliwell, B., Oxidative stress and cancer: have we moved forward?Biochem J, 2007, 401, (1), 1-11. (Pubitemid 46115897)
18. Valko, M.; Izakovic, M.; Mazur, M.; Rhodes, C.J.; Telser, J., Role of oxygen radicals in DNA damage and cancer incidence.Mol Cell Biochem, 2004, 266, (1-2), 37-56. (Pubitemid 39562306)
19. Venardos, K.M.; Perkins, A.; Headrick, J.; Kaye, D.M., Myocardial ischemia- reperfusion injury, antioxidant enzyme systems, and selenium: a review. Curr Med Chem, 2007, 14, (14), 1539-1549. (Pubitemid 46902214)
20. Flamm, E.S.; Demopoulos, H.B.; Seligman, M.L.; Poser, R.G.; Ransohoff, J., Free radicals in cerebral ischemia.Stroke, 1978, 9, (5), 445-447. (Pubitemid 8389070)
21. Heo, J.H.; Han, S.W.; Lee, S.K., Free radicals as triggers of brain edema formation after stroke.Free Radic Biol Med, 2005, 39, (1), 51-70.
22. Hill, M.F., Emerging role for antioxidant therapy in protection against diabetic cardiac complications: experimental and clinical evidence for utilization of classic and new antioxidants.Curr Cardiol Rev, 2008, 4, (4), 259-268.
23. Firuzi, O.; Fuksa, L.; Spadaro, C.; Bousova, I.; Riccieri, V.; Spadaro, A.; Petrucci, R.; Marrosu, G.; Saso, L., Oxidative stress parameters in different systemic rheumatic diseases.J Pharm Pharmacol, 2006, 58, (7), 951-957. (Pubitemid 43967112)
24. Firuzi, O.; Spadaro, A.; Spadaro, C.; Riccieri, V.; Petrucci, R.; Marrosu, G.; Saso, L., Protein oxidation markers in the serum and synovial fluid of psoriatic arthritis patients.J Clin Lab Anal, 2008, 22, (3), 210-215. (Pubitemid 351813129)
25. Riccieri, V.; Spadaro, A.; Fuksa, L.; Firuzi, O.; Saso, L.; Valesini, G., Specific oxidative stress parameters differently correlate with nailfold capillaroscopy changes and organ involvement in systemic sclerosis.Clin Rheumatol, 2008, 27, (2), 225-230.
26. Mirshafiey, A.; Mohsenzadegan, M., Antioxidant therapy in multiple sclerosis. Immunopharmacol Immunotoxicol, 2009, 31, (1), 13-29.
27. Halliwell, B., Flavonoids: a re-run of the carotenoids story?Novartis Found Symp, 2007, 282, 93-101; discussion 101-104, 212-108.
28. Halliwell, B., The wanderings of a free radical.Free Radic Biol Med, 2009, 46, (5), 531-542.
29. Babior, B.M., NADPH oxidase.Curr Opin Immunol, 2004, 16, (1), 42-47. (Pubitemid 38198116)
30. Golbidi, S.; Laher, I., Antioxidant therapy in human endocrine disorders.Med Sci Monit, 2009, 16, (1), RA9-24.
31. Huxley, R.R.; Neil, H.A., The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur J Clin Nutr, 2003, 57, (8), 904-908. (Pubitemid 36987238)
32. Hertog, M.G.; Feskens, E.J.; Hollman, P.C.; Katan, M.B.; Kromhout, D., Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study.Lancet, 1993, 342, (8878), 1007-1011. (Pubitemid 23314801)
33. Hirvonen, T.; Pietinen, P.; Virtanen, M.; Ovaskainen, M.L.; Hakkinen, S.; Albanes, D.; Virtamo, J., Intake of flavonols and flavones and risk of coronary heart disease in male smokers.Epidemiology, 2001, 12, (1), 62-67. (Pubitemid 32006463)
34. Geleijnse, J.M.; Launer, L.J.; Van der Kuip, D.A.; Hofman, A.; Witteman, J.C., Inverse association of tea and flavonoid intakes with incident myocardial infarction: the Rotterdam Study.Am J Clin Nutr, 2002, 75, (5), 880-886. (Pubitemid 34441257)
35. Mukamal, K.J.; Maclure, M.; Muller, J.E.; Sherwood, J.B.; Mittleman, M.A., Tea consumption and mortality after acute myocardial infarction. Circulation, 2002, 105, (21), 2476-2481. (Pubitemid 34568967)
36. Diplock, A.T., Antioxidant nutrients and disease prevention: an overview.Am J Clin Nutr, 1991, 53, (1 Suppl), 189S-193S.
37. de Lau, L.M.; Koudstaal, P.J.; Witteman, J.C.; Hofman, A.; Breteler, M.M., Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology, 2006, 67, (2), 315-318. (Pubitemid 44305422)
38. Engelhart, M.J.; Geerlings, M.I.; Ruitenberg, A.; van Swieten, J.C.; Hofman, A.; Witteman, J.C.; Breteler, M.M., Dietary intake of antioxidants and risk of Alzheimer disease.JAMA, 2002, 287, (24), 3223-3229. (Pubitemid 34686103)
39. Ascherio, A.; Weisskopf, M.G.; O'Reilly E, J.; Jacobs, E.J.; McCullough, M.L.; Calle, E.E.; Cudkowicz, M.; Thun, M.J., Vitamin E intake and risk of amyotrophic lateral sclerosis.Ann Neurol, 2005, 57, (1), 104-110. (Pubitemid 40053321)
40. Bjelakovic, G.; Nikolova, D.; Simonetti, R.G.; Gluud, C., Antioxidant supplements for preventing gastrointestinal cancers.Cochrane Database Syst Rev, 2008, (3), CD004183.
41. Lirussi, F.; Azzalini, L.; Orando, S.; Orlando, R.; Angelico, F., Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev, 2007, (1), CD004996.
42. Orrell, R.W.; Lane, R.J.; Ross, M., Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease.Cochrane Database Syst Rev, 2007, (1), CD002829.
43. Farinotti, M.; Simi, S.; Di Pietrantonj, C.; McDowell, N.; Brait, L.; Lupo, D.; Filippini, G., Dietary interventions for multiple sclerosis.Cochrane Database Syst Rev, 2007, (1), CD004192.
44. Rambaldi, A.; Gluud, C., S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev, 2006, (2), CD002235.
45. Evans, J.R.; Henshaw, K., Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.Cochrane Database Syst Rev, 2008, (1), CD000253.
46. Shaheen, S.O.; Newson, R.B.; Rayman, M.P.; Wong, A.P.; Tumilty, M.K.; Phillips, J.M.; Potts, J.F.; Kelly, F.J.; White, P.T.; Burney, P.G., Randomised, double blind, placebo-controlled trial of selenium supplementation in adult asthma.Thorax, 2007, 62, (6), 483-490. (Pubitemid 46910125)
47. Shuaib, A.; Lees, K.R.; Lyden, P.; Grotta, J.; Davalos, A.; Davis, S.M.; Diener, H.C.; Ashwood, T.; Wasiewski, W.W.; Emeribe, U., NXY-059 for the treatment of acute ischemic stroke.N Engl J Med, 2007, 357, (6), 562-571. (Pubitemid 47236281)
48. Cocheme, H.M.; Murphy, M.P., Can antioxidants be effective therapeutics? Curr Opin Investig Drugs, 2010, 11, (4), 426-431.
49. Iannitti, T.; Palmieri, B., Antioxidant therapy effectiveness: an up to date.Eur Rev Med Pharmacol Sci, 2009, 13, (4), 245-278.
50. Li, X.J.; Gao, N.; Zhang, H.Y., Natural inspirations for antioxidant drug discovery.Drug Discov Today, 2009, 14, (19-20), 910-912.
51. Watanabe, T.; Tahara, M.; Todo, S., The novel antioxidant edaravone: from bench to bedside.Cardiovasc Ther, 2008, 26, (2), 101-114. (Pubitemid 351952827)
52. Yamamoto, T.; Yuki, S.; Watanabe, T.; Mitsuka, M.; Saito, K.I.; Kogure, K., Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia.Brain Res, 1997, 762, (1-2), 240-242. (Pubitemid 27315958)
53. Ono, S.; Okazaki, K.; Sakurai, M.; Inoue, Y., Density Functional Study of the Radical Reactions of 3-Methyl-1-phenyl-2-pyrazolin-5-one (MCI-186): Implication for the Biological Function of MCI-186 as a Highly Potent Antioxidative Radical Scavenger.The Journal of physical chemistry, 1997, 101, (20), 3769-3775. (Pubitemid 127598730)
54. Nishinaka, Y.; Mori, H.; Endo, N.; Miyoshi, T.; Yamashita, K.; Adachi, S.; Arai, T., Edaravone directly reacts with singlet oxygen and protects cells from attack.Life Sci, 2010, 86, (21-22), 808-813.
55. Edaravone-Acute-Infarction-Study-Group, Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters.Cerebrovasc Dis, 2003, 15, (3), 222-229.
56. Abe, S.; Kirima, K.; Tsuchiya, K.; Okamoto, M.; Hasegawa, T.; Houchi, H.; Yoshizumi, M.; Tamaki, T., The reaction rate of edaravone (3-methyl-1- phenyl-2-pyrazolin-5-one (MCI-186)) with hydroxyl radical.Chem Pharm Bull (Tokyo), 2004, 52, (2), 186-191. (Pubitemid 41656750)
57. Yamamoto, Y.; Kuwahara, T.; Watanabe, K.; Watanabe, K., Antioxidant activity of 3-methyl-1-phenyl-2-pyrazolin-5-one.Redox Report 1996, 2, 333-338. (Pubitemid 126684602)
58. Zhang, N.; Komine-Kobayashi, M.; Tanaka, R.; Liu, M.; Mizuno, Y.; Urabe, T., Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain.Stroke, 2005, 36, (10), 2220-2225. (Pubitemid 41429250)
59. Yoshida, H.; Yanai, H.; Namiki, Y.; Fukatsu-Sasaki, K.; Furutani, N.; Tada, N., Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury.CNS Drug Rev, 2006, 12, (1), 9-20. (Pubitemid 44133577)
60. Higashi, Y., Edaravone for the treatment of acute cerebral infarction: role of endothelium-derived nitric oxide and oxidative stress.Expert Opin Pharmacother, 2009, 10, (2), 323-331.
61. Suda, S.; Igarashi, H.; Arai, Y.; Andou, J.; Chishiki, T.; Katayama, Y., Effect of edaravone, a free radical scavenger, on ischemic cerebral edema assessed by magnetic resonance imaging.Neurol Med Chir (Tokyo), 2007, 47, (5), 197-201; discussion 201-192. (Pubitemid 46827882)
62. Unno, Y.; Katayama, M.; Shimizu, H., Does functional outcome in acute ischaemic stroke patients correlate with the amount of free-radical scavenger treatment? A retrospective study of edaravone therapy.Clin Drug Investig, 2010, 30, (3), 143-155.
63. Ohta, Y.; Takamatsu, K.; Fukushima, T.; Ikegami, S.; Takeda, I.; Ota, T.; Goto, K.; Abe, K., Efficacy of the free radical scavenger, edaravone, for motor palsy of acute lacunar infarction.Intern Med, 2009, 48, (8), 593-596.
64. Mishina, M.; Komaba, Y.; Kobayashi, S.; Tanaka, N.; Kominami, S.; Fukuchi, T.; Mizunari, T.; Hamamoto, M.; Teramoto, A.; Katayama, Y., Efficacy of edaravone, a free radical scavenger, for the treatment of acute lacunar infarction. Neurol Med Chir (Tokyo), 2005, 45, (7), 344-348; discussion 348. (Pubitemid 41301697)
65. Inatomi, Y.; Takita, T.; Yonehara, T.; Fujioka, S.; Hashimoto, Y.; Hirano, T.; Uchino, M., Efficacy of edaravone in cardioembolic stroke.Intern Med, 2006, 45, (5), 253-257.
66. Toyoda, K.; Fujii, K.; Kamouchi, M.; Nakane, H.; Arihiro, S.; Okada, Y.; Ibayashi, S.; Iida, M., Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion.J Neurol Sci, 2004, 221, (1-2), 11-17. (Pubitemid 38721285)
67. Noor, J.I.; Ikeda, T.; Mishima, K.; Aoo, N.; Ohta, S.; Egashira, N.; Iwasaki, K.; Fujiwara, M.; Ikenoue, T., Short-term administration of a new free radical scavenger, edaravone, is more effective than its long-term administration for the treatment of neonatal hypoxic-ischemic encephalopathy.Stroke, 2005, 36, (11), 2468-2474. (Pubitemid 41566979)
68. Ishikawa, A.; Yoshida, H.; Metoki, N.; Toki, T.; Imaizumi, T.; Matsumiya, T.; Yamashita, K.; Taima, K.; Satoh, K., Edaravone inhibits the expression of vascular endothelial growth factor in human astrocytes exposed to hypoxia. Neurosci Res, 2007, 59, (4), 406-412. (Pubitemid 350011198)
69. Kikuchi, K.; Tancharoen, S.; Matsuda, F.; Biswas, K.K.; Ito, T.; Morimoto, Y.; Oyama, Y.; Takenouchi, K.; Miura, N.; Arimura, N.; Nawa, Y.; Meng, X.; Shrestha, B.; Arimura, S.; Iwata, M.; Mera, K.; Sameshima, H.; Ohno, Y.; Maenosono, R.; Tajima, Y.; Uchikado, H.; Kuramoto, T.; Nakayama, K.; Shigemori, M.; Yoshida, Y.; Hashiguchi, T.; Maruyama, I.; Kawahara, K., Edaravone attenuates cerebral ischemic injury by suppressing aquaporin- 4.Biochem Biophys Res Commun, 2009, 390, (4), 1121-1125.
70. Takahashi, R., Edaravone in ALS.Exp Neurol, 2009, 217, (2), 235-236.
71. Ogasawara, K.; Inoue, T.; Kobayashi, M.; Endo, H.; Fukuda, T.; Ogawa, A., Pretreatment with the free radical scavenger edaravone prevents cerebral hyperperfusion after carotid endarterectomy.Neurosurgery, 2004, 55, (5), 1060-1067.
72. Tsujita, K.; Shimomura, H.; Kawano, H.; Hokamaki, J.; Fukuda, M.; Yamashita, T.; Hida, S.; Nakamura, Y.; Nagayoshi, Y.; Sakamoto, T.; Yoshimura, M.; Arai, H.; Ogawa, H., Effects of edaravone on reperfusion injury in patients with acute myocardial infarction.Am J Cardiol, 2004, 94, (4), 481-484. (Pubitemid 39120000)
73. Higashi, Y.; Jitsuiki, D.; Chayama, K.; Yoshizumi, M., Edaravone (3- methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases.Recent Pat Cardiovasc Drug Discov, 2006, 1, (1), 85-93.
74. Hishida, A., Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance. Clin Exp Nephrol, 2007, 11, (4), 292-296. (Pubitemid 350277612)
75. Schulz, J.B.; Di Prospero, N.A.; Fischbeck, K., Clinical experience with high-dose idebenone in Friedreich ataxia.J Neurol, 2009, 256 Suppl 1, 42-45.
76. Meier, T.; Buyse, G., Idebenone: an emerging therapy for Friedreich ataxia.J Neurol, 2009, 256 Suppl 1, 25-30.
77. Gutzmann, H.; Hadler, D., Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study.J Neural Transm Suppl, 1998, 54, 301-310. (Pubitemid 28539367)
78. Weyer, G.; Babej-Dolle, R.M.; Hadler, D.; Hofmann, S.; Herrmann, W.M., A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease.Neuropsychobiology, 1997, 36, (2), 73-82. (Pubitemid 27331264)
79. Gutzmann, H.; Kuhl, K.P.; Hadler, D.; Rapp, M.A., Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.Pharmacopsychiatry, 2002, 35, (1), 12-18. (Pubitemid 34135453)
80. Thal, L.J.; Grundman, M.; Berg, J.; Ernstrom, K.; Margolin, R.; Pfeiffer, E.; Weiner, M.F.; Zamrini, E.; Thomas, R.G., Idebenone treatment fails to slow cognitive decline in Alzheimer's disease.Neurology, 2003, 61, (11), 1498-1502. (Pubitemid 37505568)
81. Suno, M.; Nagaoka, A., Inhibition of lipid peroxidation by a novel compound (CV-2619) in brain mitochondria and mode of action of the inhibition. Biochem Biophys Res Commun, 1984, 125, (3), 1046-1052. (Pubitemid 15152897)
82. Suno, M.; Nagaoka, A., Inhibition of lipid peroxidation by a novel compound, idebenone (CV-2619).Jpn J Pharmacol, 1984, 35, (2), 196-198. (Pubitemid 14081884)
83. Suno, M.; Nagaoka, A., Inhibition of mitochondrial swelling and lipid peroxidation by a novel compound, idebenone (CV-2619).Jpn Pharmacol Ther, 1985, 13, 673-678.
84. Pandolfo, M., Drug Insight: antioxidant therapy in inherited ataxias.Nat Clin Pract Neurol, 2008, 4, (2), 86-96. (Pubitemid 351248066)
85. Artuch, R.; Aracil, A.; Mas, A.; Colome, C.; Rissech, M.; Monros, E.; Pineda, M., Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics, 2002, 33, (4), 190-193.
86. Di Prospero, N.A.; Baker, A.; Jeffries, N.; Fischbeck, K.H., Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial.Lancet Neurol, 2007, 6, (10), 878-886. (Pubitemid 47404985)
87. Pineda, M.; Arpa, J.; Montero, R.; Aracil, A.; Dominguez, F.; Galvan, M.; Mas, A.; Martorell, L.; Sierra, C.; Brandi, N.; Garcia-Arumi, E.; Rissech, M.; Velasco, D.; Costa, J.A.; Artuch, R., Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up.Eur J Paediatr Neurol, 2008, 12, (6), 470-475.
88. Santhera's News Release. May 20 2010: Santhera's MICONOS Trial with Catena®/Sovrima® in Friedreich's Ataxia Misses Primary Endpoint. http://www.santhera.com (Accessed July 12, 2010)
89. Buyse, G.; Mertens, L.; Van Den Hauwe, M.; Thijs, D.; De Groot, I.J.M.; Schara, U.; Ceulemans, B.; Meier, T.; Goemans, N., Double-Blind Randomized Controlled Trial of SNT-MC17/Idebenone in Duchenne Muscular Dystrophy. Poster, American Academy of Neurology, Annual Meeting, 2008.
90. Tauskela, J.S., MitoQ-a mitochondria-targeted antioxidant.IDrugs, 2007, 10, (6), 399-412.
91. Sheffner, A.L., The mucolytic action of acetylcysteine.Tuberculol Thorac Dis, 1966, 23, (2), 31-33.
92. Dodd, S.; Dean, O.; Copolov, D.L.; Malhi, G.S.; Berk, M., N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility.Expert Opin Biol Ther, 2008, 8, (12), 1955-1962.
93. Corcoran, G.B.; Wong, B.K., Role of glutathione in prevention of acetaminophen- induced hepatotoxicity by N-acetyl-L-cysteine in vivo: studies with N-acetyl-D-cysteine in mice.J Pharmacol Exp Ther, 1986, 238, (1), 54-61. (Pubitemid 16058294)
94. Aitio, M.L., N-acetylcysteine - passe-partout or much ado about nothing?Br J Clin Pharmacol., 2005, 61, (1), 5-15.
95. Dekhuijzen, P.N.; van Beurden, W.J., The role for N-acetylcysteine in the management of COPD.Int J Chron Obstruct Pulmon Dis, 2006, 1, (2), 99-106.
96. Sadowska, A.M.; Verbraecken, J.; Darquennes, K.; De Backer, W.A., Role of N-acetylcysteine in the management of COPD.Int J Chron Obstruct Pulmon Dis, 2006, 1, (4), 425-434.
97. Grandjean, E.M.; Berthet, P.; Ruffmann, R.; Leuenberger, P., Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther, 2000, 22, (2), 209-221. (Pubitemid 30152100)
98. Stey, C.; Steurer, J.; Bachmann, S.; Medici, T.C.; Tramer, M.R., The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J, 2000, 16, (2), 253-262. (Pubitemid 30624944)
99. Decramer, M.; Rutten-van Molken, M.; Dekhuijzen, P.N.; Troosters, T.; van Herwaarden, C.; Pellegrino, R.; van Schayck, C.P.; Olivieri, D.; Del Donno, M.; De Backer, W.; Lankhorst, I.; Ardia, A., Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.Lancet, 2005, 365, (9470), 1552-1560. (Pubitemid 40615404)
100. Demedts, M.; Behr, J.; Buhl, R.; Costabel, U.; Dekhuijzen, R.; Jansen, H.M.; MacNee, W.; Thomeer, M.; Wallaert, B.; Laurent, F.; Nicholson, A.G.; Verbeken, E.K.; Verschakelen, J.; Flower, C.D.; Capron, F.; Petruzzelli, S.; De Vuyst, P.; van den Bosch, J.M.; Rodriguez-Becerra, E.; Corvasce, G.; Lankhorst, I.; Sardina, M.; Montanari, M., High-dose acetylcysteine in idiopathic pulmonary fibrosis.N Engl J Med, 2005, 353, (21), 2229-2242. (Pubitemid 41697286)
101. Fishbane, S., N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol, 2008, 3, (1), 281-287.
102. Tepel, M.; Zidek, W., N-Acetylcysteine in nephrology; contrast nephropathy and beyond.Curr Opin Nephrol Hypertens, 2004, 13, (6), 649-654. (Pubitemid 39506914)
103. Brown, J.R.; Block, C.A.; Malenka, D.J.; O'Connor, G.T.; Schoolwerth, A.C.; Thompson, C.A., Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis.JACC Cardiovasc Interv, 2009, 2, (11), 1116-1124.
104. Bagshaw, S.M.; McAlister, F.A.; Manns, B.J.; Ghali, W.A., Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence.Arch Intern Med, 2006, 166, (2), 161-166. (Pubitemid 43144938)
105. Vaitkus, P.T.; Brar, C., N-acetylcysteine in the prevention of contrastinduced nephropathy: publication bias perpetuated by meta-analyses.Am Heart J, 2007, 153, (2), 275-280. (Pubitemid 46096863)
106. Tirouvanziam, R.; Conrad, C.K.; Bottiglieri, T.; Herzenberg, L.A.; Moss, R.B., High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis.Proc Natl Acad Sci U S A, 2006, 103, (12), 4628-4633.
107. Berk, M.; Copolov, D.L.; Dean, O.; Lu, K.; Jeavons, S.; Schapkaitz, I.; Anderson-Hunt, M.; Bush, A.I., N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial.Biol Psychiatry, 2008, 64, (6), 468-475.
108. Berk, M.; Copolov, D.; Dean, O.; Lu, K.; Jeavons, S.; Schapkaitz, I.; Anderson- Hunt, M.; Judd, F.; Katz, F.; Katz, P.; Ording-Jespersen, S.; Little, J.; Conus, P.; Cuenod, M.; Do, K.Q.; Bush, A.I., N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebocontrolled trial.Biol Psychiatry, 2008, 64, (5), 361-368.
109. Duijvestijn, Y.C.; Mourdi, N.; Smucny, J.; Pons, G.; Chalumeau, M., Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. Cochrane Database Syst Rev, 2009, (1), CD003124.
110. McKay, A.; Cassidy, D.; Sutherland, F.; Dixon, E., Clinical results of Nacetylcysteine after major hepatic surgery: a review.J Hepatobiliary Pancreat Surg, 2008, 15, (5), 473-478.
111. Singh, U.; Jialal, I., Alpha-lipoic acid supplementation and diabetes.Nutr Rev, 2008, 66, (11), 646-657.
112. Tesfaye, S., Advances in the management of diabetic peripheral neuropathy. Curr Opin Support Palliat Care, 2009, 3, (2), 136-143.
113. Steliana, G.; Carole, R.; Catherine, V.; Marianne, Z.; Yves, C.; Luc, R., Antioxidant properties of an endogenous thiol: alpha-lipoic acid, useful in the prevention of cardio-vascular diseases.J Cardiovasc Pharmacol, 2009.
114. Holmquist, L.; Stuchbury, G.; Berbaum, K.; Muscat, S.; Young, S.; Hager, K.; Engel, J.; Munch, G., Lipoic acid as a novel treatment for Alzheimer's disease and related dementias.Pharmacol Ther, 2007, 113, (1), 154-164. (Pubitemid 44969927)
115. Ziegler, D.; Nowak, H.; Kempler, P.; Vargha, P.; Low, P.A., Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis.Diabet Med, 2004, 21, (2), 114-121. (Pubitemid 38221809)
116. Stirban, A., Drugs for the treatment of diabetes complications. Zycose: a new player in the field?Drugs Today (Barc), 2008, 44, (10), 783-796.
117. Vossler, S.; Fullert, S.; Schneider, F.; Haak, E.; Haak, T.; Samigullin, R.; Tritschler, H.; Tooke, J.E.; Konrad, T., Pharmacodynamic effects of orally administered dexlipotam on endothelial function in type 2-diabetic patients. Int J Clin Pharmacol Ther, 2007, 45, (7), 385-393. (Pubitemid 47045481)
118. Firuzi, O.; Lacanna, A.; Petrucci, R.; Marrosu, G.; Saso, L., Evaluation of the antioxidant activity of flavonoids by "ferric reducing antioxidant power" assay and cyclic voltammetry.Biochim Biophys Acta, 2005, 1721, (1-3), 174-184. (Pubitemid 40093525)
119. Firuzi, O.; Mladenka, P.; Petrucci, R.; Marrosu, G.; Saso, L., Hypochlorite scavenging activity of flavonoids.J Pharm Pharmacol, 2004, 56, (6), 801-807. (Pubitemid 38801696)
120. Pulido, R.; Bravo, L.; Saura-Calixto, F., Antioxidant activity of dietary polyphenols as determined by a modified ferric reducing/antioxidant power assay.J Agric Food Chem, 2000, 48, (8), 3396-3402.
121. Benavente-Garcia, O.; Castillo, J., Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and antiinflammatory activity.J Agric Food Chem, 2008, 56, (15), 6185-6205.
122. Peters, U.; Poole, C.; Arab, L., Does tea affect cardiovascular disease? A meta-analysis.Am J Epidemiol, 2001, 154, (6), 495-503. (Pubitemid 32867948)
123. Mennen, L.I.; Sapinho, D.; de Bree, A.; Arnault, N.; Bertrais, S.; Galan, P.; Hercberg, S., Consumption of foods rich in flavonoids is related to a decreased cardiovascular risk in apparently healthy French women. J Nutr, 2004, 134, (4), 923-926. (Pubitemid 38456265)
124. Riboli, E.; Norat, T., Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk.Am J Clin Nutr, 2003, 78, (3 Suppl), 559S- 569S. (Pubitemid 40012550)
125. Knekt, P.; Kumpulainen, J.; Jarvinen, R.; Rissanen, H.; Heliovaara, M.; Reunanen, A.; Hakulinen, T.; Aromaa, A., Flavonoid intake and risk of chronic diseases.Am J Clin Nutr, 2002, 76, (3), 560-568. (Pubitemid 34920833)
126. Hooper, L.; Kroon, P.A.; Rimm, E.B.; Cohn, J.S.; Harvey, I.; Le Cornu, K.A.; Ryder, J.J.; Hall, W.L.; Cassidy, A., Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials.Am J Clin Nutr, 2008, 88, (1), 38-50. (Pubitemid 351988681)
127. Williamson, G.; Manach, C., Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies.Am J Clin Nutr, 2005, 81, (1 Suppl), 243S-255S.
128. Halliwell, B.; Rafter, J.; Jenner, A., Health promotion by flavonoids, tocopherols, tocotrienols, and other phenols: direct or indirect effects? Antioxidant or not?Am J Clin Nutr, 2005, 81, (1 Suppl), 268S-276S.
129. Lotito, S.B.; Frei, B., Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon? Free Radic Biol Med, 2006, 41, (12), 1727-1746. (Pubitemid 44839139)
130. Williamson, G.; Barron, D.; Shimoi, K.; Terao, J., In vitro biological properties of flavonoid conjugates found in vivo.Free Radic Res, 2005, 39, (5), 457-469. (Pubitemid 40711878)
131. Jenner, A.M.; Rafter, J.; Halliwell, B., Human fecal water content of phenolics: the extent of colonic exposure to aromatic compounds.Free Radic Biol Med, 2005, 38, (6), 763-772. (Pubitemid 40249747)
132. Bettuzzi, S.; Brausi, M.; Rizzi, F.; Castagnetti, G.; Peracchia, G.; Corti, A., Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study.Cancer Res, 2006, 66, (2), 1234-1240. (Pubitemid 43165995)
133. Khan, N.; Adhami, V.M.; Mukhtar, H., Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies.Nutr Cancer, 2009, 61, (6), 836-841.
134. Velayutham, P.; Babu, A.; Liu, D., Green Tea Catechins and Cardiovascular Health: An Update.Curr Med Chem., 2008, 15, (18), 1840-1850.
135. Nagao, T.; Meguro, S.; Hase, T.; Otsuka, K.; Komikado, M.; Tokimitsu, I.; Yamamoto, T.; Yamamoto, K., A catechin-rich beverage improves obesity and blood glucose control in patients with type 2 diabetes.Obesity (Silver Spring), 2009, 17, (2), 310-317.
136. Maki, K.C.; Reeves, M.S.; Farmer, M.; Yasunaga, K.; Matsuo, N.; Katsuragi, Y.; Komikado, M.; Tokimitsu, I.; Wilder, D.; Jones, F.; Blumberg, J.B.; Cartwright, Y., Green tea catechin consumption enhances exercise-induced abdominal fat loss in overweight and obese adults.J Nutr, 2009, 139, (2), 264-270.
137. Wang, H.; Wen, Y.; Du, Y.; Yan, X.; Guo, H.; Rycroft, J.A.; Boon, N.; Kovacs, E.M.; Mela, D.J., Effects of catechin enriched green tea on body composition.Obesity (Silver Spring), 2009, 18, (4), 773-779.
138. Li, S.H.; Liu, X.X.; Bai, Y.Y.; Wang, X.J.; Sun, K.; Chen, J.Z.; Hui, R.T., Effect of oral isoflavone supplementation on vascular endothelial function in postmenopausal women: a meta-analysis of randomized placebo-controlled trials.Am J Clin Nutr, 2010, 91, (2), 480-486.
139. Taku, K.; Melby, M.K.; Kurzer, M.S.; Mizuno, S.; Watanabe, S.; Ishimi, Y., Effects of soy isoflavone supplements on bone turnover markers in menopausal women: systematic review and meta-analysis of randomized controlled trials.Bone, 2010, 47, (2), 413-423.
140. Bitto, A.; Granese, R.; Triolo, O.; Villari, D.; Maisano, D.; Giordano, D.; Altavilla, D.; Marini, H.; Adamo, E.B.; Nicotina, P.A.; D'Anna, R.; Squadrito, F., Genistein aglycone: A new therapeutic approach to reduce endometrial hyperplasia.Phytomedicine, 2010.
141. Marini, H.; Bitto, A.; Altavilla, D.; Burnett, B.P.; Polito, F.; Di Stefano, V.; Minutoli, L.; Atteritano, M.; Levy, R.M.; Frisina, N.; Mazzaferro, S.; Frisina, A.; D'Anna, R.; Cancellieri, F.; Cannata, M.L.; Corrado, F.; Lubrano, C.; Marini, R.; Adamo, E.B.; Squadrito, F., Efficacy of genistein aglycone on some cardiovascular risk factors and homocysteine levels: A follow-up study.Nutr Metab Cardiovasc Dis, 2010, 20, (5), 332-340.
142. Liu, Z.M.; Chen, Y.M.; Ho, S.C.; Ho, Y.P.; Woo, J., Effects of soy protein and isoflavones on glycemic control and insulin sensitivity: a 6-mo doubleblind, randomized, placebo-controlled trial in postmenopausal Chinese women with prediabetes or untreated early diabetes.Am J Clin Nutr, 2010, 91, (5), 1394-1401.
143. Heinz, S.A.; Henson, D.A.; Austin, M.D.; Jin, F.; Nieman, D.C., Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial.Pharmacol Res, 2010, 62, (3), 237-242.
144. Egert, S.; Boesch-Saadatmandi, C.; Wolffram, S.; Rimbach, G.; Muller, M.J., Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype.J Nutr, 2010, 140, (2), 278-284.
145. Ossola, B.; Kaariainen, T.M.; Mannisto, P.T., The multiple faces of quercetin in neuroprotection.Expert Opin Drug Saf, 2009, 8, (4), 397-409.
146. Coleridge-Smith, P.; Lok, C.; Ramelet, A.A., Venous leg ulcer: a metaanalysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg, 2005, 30, (2), 198-208. (Pubitemid 40932020)
147. Lyseng-Williamson, K.A.; Perry, C.M., Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.Drugs, 2003, 63, (1), 71-100. (Pubitemid 36132514)
148. Garner, R.C.; Garner, J.V.; Gregory, S.; Whattam, M.; Calam, A.; Leong,
149. Bergan, J.J., Chronic venous insufficiency and the therapeutic effects of Daflon 500 mg.Angiology, 2005, 56 Suppl 1, S21-24. (Pubitemid 41376944)
150. Jantet, G., Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids.Angiology, 2002, 53, (3), 245-256.
151. Gohel, M.S.; Davies, A.H., Pharmacological agents in the treatment of venous disease: an update of the available evidence.Curr Vasc Pharmacol, 2009, 7, (3), 303-308.
152. Kearon, C.; Kahn, S.R.; Agnelli, G.; Goldhaber, S.; Raskob, G.E.; Comerota, A.J., Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest, 2008, 133, (6 Suppl), 454S-545S. (Pubitemid 351892971)
153. Meyer, O., Safety of use of Daflon 500 mg confirmed by acquired experience and new research. Phlebology Suppl, 1992, 2, 64-68.
154. Sirlak, M.; Akar, A.R.; Eryilmaz, S.; Cetinkanat, E.K.; Ozcinar, E.; Kaya, B.; Elhan, A.H.; Ozyurda, U., Micronized purified flavonoid fraction in pretreating CABG patients.Tex Heart Inst J, 2010, 37, (2), 172-177.
155. Akbulut, B., Calcium dobesilate and oxerutin: effectiveness of combination therapy.Phlebology, 2010, 25, (2), 66-71.
156. Belcaro, G.; Cesarone, M.R.; Ledda, A.; Cacchio, M.; Ruffini, I.; Ricci, A.; Ippolito, E.; Di Renzo, A.; Dugall, M.; Corsi, M.; Marino Santarelli, A.R.; Grossi, M.G., 5-Year control and treatment of edema and increased capillary filtration in venous hypertension and diabetic microangiopathy using O- (beta-hydroxyethyl)-rutosides: a prospective comparative clinical registry. Angiology, 2008, 59 Suppl 1, 14S-20S. (Pubitemid 351253078)
157. Wadworth, A.N.; Faulds, D., Hydroxyethylrutosides. A review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders. Drugs, 1992, 44, (6), 1013-1032. (Pubitemid 23024551)
158. Dhiman, R.K.; Chawla, Y.K., Herbal medicines for liver diseases.Dig Dis Sci, 2005, 50, (10), 1807-1812. (Pubitemid 41413894)
159. Kroll, D.J.; Shaw, H.S.; Oberlies, N.H., Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies.Integr Cancer Ther, 2007, 6, (2), 110-119. (Pubitemid 46871844)
160. Jacobs, B.P.; Dennehy, C.; Ramirez, G.; Sapp, J.; Lawrence, V.A., Milk thistle for the treatment of liver disease: a systematic review and metaanalysis. Am J Med, 2002, 113, (6), 506-515. (Pubitemid 35335804)
161. Saller, R.; Brignoli, R.; Melzer, J.; Meier, R., An updated systematic review with meta-analysis for the clinical evidence of silymarin.Forsch Komplementmed, 2008, 15, (1), 9-20. (Pubitemid 351364393)
162. Raina, K.; Agarwal, R., Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms.Acta Pharmacol Sin, 2007, 28, (9), 1466-1475. (Pubitemid 47366688)
163. Ramasamy, K.; Agarwal, R., Multitargeted therapy of cancer by silymarin. Cancer Lett, 2008, 269, (2), 352-362.
164. Mann, C.D.; Neal, C.P.; Garcea, G.; Manson, M.M.; Dennison, A.R.; Berry, D.P., Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis.Eur J Cancer Prev, 2009, 18, (1), 13-25.
165. Levy, R.M.; Saikovsky, R.; Shmidt, E.; Khokhlov, A.; Burnett, B.P., Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study.Nutr Res, 2009, 29, (5), 298-304.
166. Altavilla, D.; Squadrito, F.; Bitto, A.; Polito, F.; Burnett, B.P.; Di Stefano, V.; Minutoli, L., Flavocoxid, a dual inhibitor of cyclooxygenase and 5- lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxinstimulated macrophages.Br J Pharmacol, 2009, 157, (8), 1410-1418.
167. Pillai, L.; Burnett, B.P.; Levy, R.M., GOAL: multicenter, open-label, postmarketing study of flavocoxid, a novel dual pathway inhibitor antiinflammatory agent of botanical origin.Curr Med Res Opin, 2010, 26, (5), 1055-1063.
168. Kim, J.; Lee, H.J.; Lee, K.W., Naturally occurring phytochemicals for the prevention of Alzheimer's disease.J Neurochem, 2010, 112, (6), 1415-1430.
169. Singh, M.; Arseneault, M.; Sanderson, T.; Murthy, V.; Ramassamy, C., Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms.J Agric Food Chem, 2008, 56, (13), 4855-4873. (Pubitemid 352039080)
170. Bishayee, A.; Politis, T.; Darvesh, A.S., Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma.Cancer Treat Rev, 2010, 36, (1), 43-53.
171. Goel, A.; Kunnumakkara, A.B.; Aggarwal, B.B., Curcumin as "Curecumin": from kitchen to clinic.Biochem Pharmacol, 2008, 75, (4), 787-809.
172. Lieberman, S.; Bruning, N. The Real Vitamin & Mineral Book. Avery Pub. Group, 1990.
173. Rimm, E.B.; Stampfer, M.J.; Ascherio, A.; Giovannucci, E.; Colditz, G.A.; Willett, W.C., Vitamin E consumption and the risk of coronary heart disease in men.N Engl J Med, 1993, 328, (20), 1450-1456. (Pubitemid 23143847)
174. Stampfer, M.J.; Hennekens, C.H.; Manson, J.E.; Colditz, G.A.; Rosner, B.; Willett, W.C., Vitamin E consumption and the risk of coronary disease in women.N Engl J Med, 1993, 328, (20), 1444-1449. (Pubitemid 23143846)
175. Knekt, P.; Reunanen, A.; Jarvinen, R.; Seppanen, R.; Heliovaara, M.; Aromaa, A., Antioxidant vitamin intake and coronary mortality in a longitudinal population study.Am J Epidemiol, 1994, 139, (12), 1180-1189. (Pubitemid 24184411)
176. Todd, S.; Woodward, M.; Tunstall-Pedoe, H.; Bolton-Smith, C., Dietary antioxidant vitamins and fiber in the etiology of cardiovascular disease and all-causes mortality: results from the Scottish Heart Health Study.Am J Epidemiol, 1999, 150, (10), 1073-1080. (Pubitemid 29531943)
177. Rumbold, A.; Duley, L.; Crowther, C.A.; Haslam, R.R., Antioxidants for preventing pre-eclampsia.Cochrane Database Syst Rev, 2008, (1), CD004227.
178. Bjelakovic, G.; Nikolova, D.; Gluud, L.L.; Simonetti, R.G.; Gluud, C., Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.JAMA, 2007, 297, (8), 842-857. (Pubitemid 46333949)
179. Bjelakovic, G.; Nikolova, D.; Simonetti, R.G.; Gluud, C., Systematic review: primary and secondary prevention of gastrointestinal cancers with antioxidant supplements.Aliment Pharmacol Ther, 2008, 28, (6), 689-703.
180. Vivekananthan, D.P.; Penn, M.S.; Sapp, S.K.; Hsu, A.; Topol, E.J., Use of antioxidant vitamins for the prevention of cardiovascular disease: metaanalysis of randomised trials.Lancet, 2003, 361, (9374), 2017-2023. (Pubitemid 36695043)
181. Miller, E.R., 3rd; Pastor-Barriuso, R.; Dalal, D.; Riemersma, R.A.; Appel, L.J.; Guallar, E., Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality.Ann Intern Med, 2005, 142, (1), 37-46.
182. Gerss, J.; Kopcke, W., The questionable association of vitamin E supplementation and mortality-inconsistent results of different meta-analytic approaches. Cell Mol Biol (Noisy-le-grand), 2009, 55 Suppl, OL1111-1120.
183. Goralczyk, R., Beta-carotene and lung cancer in smokers: review of hypotheses and status of research.Nutr Cancer, 2009, 61, (6), 767-774.
184. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group, The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group.N Engl J Med, 1994, 330, (15), 1029-1035.
185. Boaz, M.; Smetana, S.; Weinstein, T.; Matas, Z.; Gafter, U.; Iaina, A.; Knecht, A.; Weissgarten, Y.; Brunner, D.; Fainaru, M.; Green, M.S., Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.Lancet, 2000, 356, (9237), 1213-1218.
186. Stephens, N.G.; Parsons, A.; Schofield, P.M.; Kelly, F.; Cheeseman, K.; Mitchinson, M.J., Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS).Lancet, 1996, 347, (9004), 781-786. (Pubitemid 26091640)
187. Yusuf, S.; Dagenais, G.; Pogue, J.; Bosch, J.; Sleight, P., Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.N Engl J Med, 2000, 342, (3), 154-160. (Pubitemid 30051646)
188. GISSI Prevenzione Investigators, Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.Lancet, 1999, 354, (9177), 447-455.
189. Shekelle, P.G.; Morton, S.C.; Jungvig, L.K.; Udani, J.; Spar, M.; Tu, W.; M, J.S.; Coulter, I.; Newberry, S.J.; Hardy, M., Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease.J Gen Intern Med, 2004, 19, (4), 380-389. (Pubitemid 38530510)
190. Violi, F.; Cangemi, R., Statin treatment as a confounding factor in human trials with vitamin E.J Nutr, 2008, 138, (6), 1179-1181. (Pubitemid 351769148)
191. Kraemer, K.; Koch, W.; Hoppe, P.P., Is all-rac-alpha-tocopherol different from RRR-alpha-tocopherol regarding cardiovascular efficacy? A metaanalysis of clinical trials.Ann N Y Acad Sci, 2004, 1031, 435-438. (Pubitemid 40361799)
192. Dallner, G.; Sindelar, P.J., Regulation of ubiquinone metabolism.Free Radic Biol Med, 2000, 29, (3-4), 285-294.
193. Singh, U.; Devaraj, S.; Jialal, I., Coenzyme Q10 supplementation and heart failure.Nutr Rev, 2007, 65, (6 Pt 1), 286-293. (Pubitemid 351804363)
194. Sandor, P.S.; Di Clemente, L.; Coppola, G.; Saenger, U.; Fumal, A.; Magis, D.; Seidel, L.; Agosti, R.M.; Schoenen, J., Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial.Neurology, 2005, 64, (4), 713-715. (Pubitemid 40261904)
195. Rosenfeldt, F.L.; Haas, S.J.; Krum, H.; Hadj, A.; Ng, K.; Leong, J.Y.; Watts, G.F., Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials.J Hum Hypertens, 2007, 21, (4), 297-306. (Pubitemid 46453530)
196. Mancuso, M.; Orsucci, D.; Volpi, L.; Calsolaro, V.; Siciliano, G., Coenzyme Q10 in neuromuscular and neurodegenerative disorders.Curr Drug Targets, 2010, 11, (1), 111-121.
197. Bonakdar, R.A.; Guarneri, E., Coenzyme Q10.Am Fam Physician, 2005, 72, (6), 1065-1070. (Pubitemid 43093261)
198. Iwamura, M.; Inamoto, N., Novel formation of nitroxide radicals by radical addition to nitrones.Bull. Chem. Soc. Jpn, 1967, 40, 703.
199. Janzen, E., Spin trapping.Acc. Chem. Res, 1971, 4, 31-40.
200. Carney, J.M.; Starke-Reed, P.E.; Oliver, C.N.; Landum, R.W.; Cheng, M.S.; Wu, J.F.; Floyd, R.A., Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl- alphaphenylnitrone. Proc Natl Acad Sci U S A, 1991, 88, (9), 3633-3636. (Pubitemid 21916677)
201. Floyd, R.A.; Kopke, R.D.; Choi, C.H.; Foster, S.B.; Doblas, S.; Towner, R.A., Nitrones as therapeutics.Free Radic Biol Med, 2008, 45, (10), 1361-1374.
202. Choi, C.H.; Chen, K.; Vasquez-Weldon, A.; Jackson, R.L.; Floyd, R.A.; Kopke, R.D., Effectiveness of 4-hydroxy phenyl N-tert-butylnitrone (4- OHPBN) alone and in combination with other antioxidant drugs in the treatment of acute acoustic trauma in chinchilla.Free Radic Biol Med, 2008, 44, (9), 1772-1784.
203. Rao, D.; Fechter, L.D., Protective effects of phenyl-N-tert-butylnitrone on the potentiation of noise-induced hearing loss by carbon monoxide.Toxicol Appl Pharmacol, 2000, 167, (2), 125-131.
204. Kopke, R.; Bielefeld, E.; Liu, J.; Zheng, J.; Jackson, R.; Henderson, D.; Coleman, J.K., Prevention of impulse noise-induced hearing loss with antioxidants. Acta Otolaryngol, 2005, 125, (3), 235-243. (Pubitemid 40477189)
205. Lees, K.R.; Zivin, J.A.; Ashwood, T.; Davalos, A.; Davis, S.M.; Diener, H.C.; Grotta, J.; Lyden, P.; Shuaib, A.; Hardemark, H.G.; Wasiewski, W.W., NXY-059 for acute ischemic stroke.N Engl J Med, 2006, 354, (6), 588-600. (Pubitemid 43209106)
206. Savitz, S.I., A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke.Exp Neurol, 2007, 205, (1), 20-25. (Pubitemid 46621180)
207. Kalaria, R.N.; Maestre, G.E.; Arizaga, R.; Friedland, R.P.; Galasko, D.; Hall, K.; Luchsinger, J.A.; Ogunniyi, A.; Perry, E.K.; Potocnik, F.; Prince, M.; Stewart, R.; Wimo, A.; Zhang, Z.X.; Antuono, P., Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors.Lancet Neurol, 2008, 7, (9), 812-826.
208. Commenges, D.; Scotet, V.; Renaud, S.; Jacqmin-Gadda, H.; Barberger- Gateau, P.; Dartigues, J.F., Intake of flavonoids and risk of dementia.Eur J Epidemiol, 2000, 16, (4), 357-363. (Pubitemid 30648741)
209. Boothby, L.A.; Doering, P.L., Vitamin C and vitamin E for Alzheimer's disease.Ann Pharmacother, 2005, 39, (12), 2073-2080.
210. Sano, M.; Ernesto, C.; Thomas, R.G.; Klauber, M.R.; Schafer, K.; Grundman, M.; Woodbury, P.; Growdon, J.; Cotman, C.W.; Pfeiffer, E.; Schneider, L.S.; Thal, L.J., A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.N Engl J Med, 1997, 336, (17), 1216-1222. (Pubitemid 27183651)
211. Ritchie, C.W.; Bush, A.I.; Mackinnon, A.; Macfarlane, S.; Mastwyk, M.; MacGregor, L.; Kiers, L.; Cherny, R.; Li, Q.X.; Tammer, A.; Carrington, D.; Mavros, C.; Volitakis, I.; Xilinas, M.; Ames, D.; Davis, S.; Beyreuther, K.; Tanzi, R.E.; Masters, C.L., Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.Arch Neurol, 2003, 60, (12), 1685-1691. (Pubitemid 37521621)
212. Hager, K.; Kenklies, M.; McAfoose, J.; Engel, J.; Munch, G., Alpha-lipoic acid as a new treatment option for Alzheimer's disease-a 48 months followup analysis.J Neural Transm Suppl, 2007, (72), 189-193.
213. Hager, K.; Marahrens, A.; Kenklies, M.; Riederer, P.; Munch, G., Alphalipoic acid as a new treatment option for Azheimer type dementia.Arch Gerontol Geriatr, 2001, 32, (3), 275-282. (Pubitemid 32505692)
214. Gray, S.L.; Anderson, M.L.; Crane, P.K.; Breitner, J.C.; McCormick, W.; Bowen, J.D.; Teri, L.; Larson, E., Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults.J Am Geriatr Soc, 2008, 56, (2), 291-295. (Pubitemid 351160681)
215. Jia, X.; McNeill, G.; Avenell, A., Does taking vitamin, mineral and fatty acid supplements prevent cognitive decline? A systematic review of randomized controlled trials.J Hum Nutr Diet, 2008, 21, (4), 317-336. (Pubitemid 352044725)
216. Malouf, R.; Areosa Sastre, A., Vitamin B12 for cognition.Cochrane Database Syst Rev, 2003, (3), CD004326.
217. Weber, C.A.; Ernst, M.E., Antioxidants, supplements, and Parkinson's disease. Ann Pharmacother, 2006, 40, (5), 935-938. (Pubitemid 43765012)
218. Storch, A.; Jost, W.H.; Vieregge, P.; Spiegel, J.; Greulich, W.; Durner, J.; Muller, T.; Kupsch, A.; Henningsen, H.; Oertel, W.H.; Fuchs, G.; Kuhn, W.; Niklowitz, P.; Koch, R.; Herting, B.; Reichmann, H., Randomized, doubleblind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.Arch Neurol, 2007, 64, (7), 938-944. (Pubitemid 47047992)
219. Lindhorst, S.; Cudkowicz, M., Is pentoxifylline safe and effective in patients with amyotrophic lateral sclerosis?Nat Clin Pract Neurol, 2006, 2, (7), 364-365. (Pubitemid 43983773)
220. Huang, H.Y.; Caballero, B.; Chang, S.; Alberg, A.; Semba, R.; Schneyer, C.; Wilson, R.F.; Cheng, T.Y.; Prokopowicz, G.; Barnes, G.J., 2nd; Vassy, J.; Bass, E.B., Multivitamin/mineral supplements and prevention of chronic disease. Evid Rep Technol Assess (Full Rep), 2006, (139), 1-117.
221. Qiao, Y.L.; Dawsey, S.M.; Kamangar, F.; Fan, J.H.; Abnet, C.C.; Sun, X.D.; Johnson, L.L.; Gail, M.H.; Dong, Z.W.; Yu, B.; Mark, S.D.; Taylor, P.R., Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial.J Natl Cancer Inst, 2009, 101, (7), 507-518.
222. Virtamo, J.; Pietinen, P.; Huttunen, J.K.; Korhonen, P.; Malila, N.; Virtanen, M.J.; Albanes, D.; Taylor, P.R.; Albert, P., Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up.JAMA, 2003, 290, (4), 476-485. (Pubitemid 37430501)
223. Lippman, S.M.; Klein, E.A.; Goodman, P.J.; Lucia, M.S.; Thompson, I.M.; Ford, L.G.; Parnes, H.L.; Minasian, L.M.; Gaziano, J.M.; Hartline, J.A.; Parsons, J.K.; Bearden, J.D., 3rd; Crawford, E.D.; Goodman, G.E.; Claudio, J.; Winquist, E.; Cook, E.D.; Karp, D.D.; Walther, P.; Lieber, M.M.; Kristal, A.R.; Darke, A.K.; Arnold, K.B.; Ganz, P.A.; Santella, R.M.; Albanes, D.; Taylor, P.R.; Probstfield, J.L.; Jagpal, T.J.; Crowley, J.J.; Meyskens, F.L., Jr.; Baker, L.H.; Coltman, C.A., Jr., Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).JAMA, 2009, 301, (1), 39-51.
224. Gallicchio, L.; Boyd, K.; Matanoski, G.; Tao, X.G.; Chen, L.; Lam, T.K.; Shiels, M.; Hammond, E.; Robinson, K.A.; Caulfield, L.E.; Herman, J.G.; Guallar, E.; Alberg, A.J., Carotenoids and the risk of developing lung cancer: a systematic review.Am J Clin Nutr, 2008, 88, (2), 372-383.
225. Wang, C.X.; Shuaib, A., Neuroprotective effects of free radical scavengers in stroke.Drugs Aging, 2007, 24, (7), 537-546. (Pubitemid 47195673)
226. Green, A.R.; Shuaib, A., Therapeutic strategies for the treatment of stroke.Drug Discov Today, 2006, 11, (15-16), 681-693. (Pubitemid 44056287)
227. Rodrigo, J.; Fernandez, A.P.; Serrano, J.; Peinado, M.A.; Martinez, A., The role of free radicals in cerebral hypoxia and ischemia.Free Radic Biol Med, 2005, 39, (1), 26-50. (Pubitemid 40740221)
228. Alexandrova, M.L.; Bochev, P.G., Oxidative stress during the chronic phase after stroke.Free Radic Biol Med, 2005, 39, (3), 297-316. (Pubitemid 40910187)
229. Hankey, G.J., Neuroprotection for acute ischaemic stroke: hope reignited. Lancet Neurol, 2006, 5, (4), 287-288.
230. Ogawa, A.; Yoshimoto, T.; Kikuchi, H.; Sano, K.; Saito, I.; Yamaguchi, T.; Yasuhara, H., Ebselen in acute middle cerebral artery occlusion: a placebocontrolled, double-blind clinical trial.Cerebrovasc Dis, 1999, 9, (2), 112-118. (Pubitemid 29084227)
231. Yamaguchi, T.; Sano, K.; Takakura, K.; Saito, I.; Shinohara, Y.; Asano, T.; Yasuhara, H., Ebselen in acute ischemic stroke: a placebo-controlled, double- blind clinical trial. Ebselen Study Group.Stroke, 1998, 29, (1), 12-17. (Pubitemid 28046934)
232. Bath, P.M.; Iddenden, R.; Bath, F.J.; Orgogozo, J.M., Tirilazad for acute ischaemic stroke.Cochrane Database Syst Rev, 2001, (4), CD002087.
233. van der Worp, H.B.; Kappelle, L.J.; Algra, A.; Bar, P.R.; Orgogozo, J.M.; Ringelstein, E.B.; Bath, P.M.; van Gijn, J., The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke.Neurology, 2002, 58, (1), 133-135. (Pubitemid 34041952)
234. Sena, E.; Wheble, P.; Sandercock, P.; Macleod, M., Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke.Stroke, 2007, 38, (2), 388-394. (Pubitemid 46184311)
235. Gutteridge, J.M.; Halliwell, B., Antioxidants: Molecules, medicines, and myths.Biochem Biophys Res Commun, 2010, 393, (4), 561-564.
236. Pechanova, O.; Simko, F., Chronic antioxidant therapy fails to ameliorate hypertension: potential mechanisms behind.J Hypertens Suppl, 2009, 27, (6), S32-36.
237. Hoshino, Y.; Mishima, M., Redox-based therapeutics for lung diseases. Antioxid Redox Signal, 2008, 10, (4), 701-704. (Pubitemid 351225907)
238. Robinson, I.; de Serna, D.G.; Gutierrez, A.; Schade, D.S., Vitamin E in humans: an explanation of clinical trial failure.Endocr Pract, 2006, 12, (5), 576-582. (Pubitemid 46456048)
239. Levy, A.P., Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy. Pharmacol Ther, 2006, 112, (2), 501-512. (Pubitemid 44486413)
240. Moradi, M.; Mojtahedzadeh, M.; Mandegari, A.; Soltan-Sharifi, M.S.; Najafi, A.; Khajavi, M.R.; Hajibabayee, M.; Ghahremani, M.H., The role of glutathione-S-transferase polymorphisms on clinical outcome of ALI/ARDS patient treated with N-acetylcysteine.Respir Med, 2009, 103, (3), 434-441.
241. Dotan, Y.; Lichtenberg, D.; Pinchuk, I., No evidence supports vitamin E indiscriminate supplementation.Biofactors, 2009, 35, (6), 469-473.
242. Verhagen, H.; de Vries, A.; Nijhoff, W.A.; Schouten, A.; van Poppel, G.; Peters, W.H.; van den Berg, H., Effect of Brussels sprouts on oxidative DNA-damage in man.Cancer Lett, 1997, 114, (1-2), 127-130. (Pubitemid 27140091)
243. Prieme, H.; Loft, S.; Nyyssonen, K.; Salonen, J.T.; Poulsen, H.E., No effect of supplementation with vitamin E, ascorbic acid, or coenzyme Q10 on oxidative DNA damage estimated by 8-oxo-7,8-dihydro-2′-deoxyguanosine excretion in smokers.Am J Clin Nutr, 1997, 65, (2), 503-507. (Pubitemid 27130759)
244. O'Reilly, J.D.; Mallet, A.I.; McAnlis, G.T.; Young, I.S.; Halliwell, B.; Sanders, T.A.; Wiseman, H., Consumption of flavonoids in onions and black tea: lack of effect on F2-isoprostanes and autoantibodies to oxidized LDL in healthy humans.Am J Clin Nutr, 2001, 73, (6), 1040-1044. (Pubitemid 32496942)
245. Egert, S.; Wolffram, S.; Bosy-Westphal, A.; Boesch-Saadatmandi, C.; Wagner, A.E.; Frank, J.; Rimbach, G.; Mueller, M.J., Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans.J Nutr, 2008, 138, (9), 1615-1621.
246. Halliwell, B., Establishing the significance and optimal intake of dietary antioxidants: the biomarker concept.Nutr Rev, 1999, 57, (4), 104-113. (Pubitemid 29206385)
247. Manach, C.; Williamson, G.; Morand, C.; Scalbert, A.; Remesy, C., Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies.Am J Clin Nutr, 2005, 81, (1 Suppl), 230S-242S.
248. Steinhubl, S.R., Why have antioxidants failed in clinical trials?Am J Cardiol, 2008, 101, (10A), 14D-19D.
249. Wingler, K.; Schmidt, H.H., Good stress, bad stress-the delicate balance in the vasculature.Dtsch Arztebl Int, 2009, 106, (42), 677-684.
250. Schafer, Z.T.; Grassian, A.R.; Song, L.; Jiang, Z.; Gerhart-Hines, Z.; Irie, H.Y.; Gao, S.; Puigserver, P.; Brugge, J.S., Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment.Nature, 2009, 461, (7260), 109-113.
251. Amagase, H., Clarifying the real bioactive constituents of garlic.J Nutr, 2006, 136, (3 Suppl), 716S-725S. (Pubitemid 43363763)
252. Zingg, J.M.; Azzi, A., Non-antioxidant activities of vitamin E.Curr Med Chem, 2004, 11, (9), 1113-1133. (Pubitemid 38585057)
253. Patel, B.D.; Welch, A.A.; Bingham, S.A.; Luben, R.N.; Day, N.E.; Khaw, K.T.; Lomas, D.A.; Wareham, N.J., Dietary antioxidants and asthma in adults.Thorax, 2006, 61, (5), 388-393. (Pubitemid 43723320)
254. Li, L.; Chen, C.Y.; Aldini, G.; Johnson, E.J.; Rasmussen, H.; Yoshida, Y.; Niki, E.; Blumberg, J.B.; Russell, R.M.; Yeum, K.J., Supplementation with lutein or lutein plus green tea extracts does not change oxidative stress in adequately nourished older adults.J Nutr Biochem, 2010, 21, (6), 544-549.
255. Coleman, J.K.; Kopke, R.D.; Liu, J.; Ge, X.; Harper, E.A.; Jones, G.E.; Cater, T.L.; Jackson, R.L., Pharmacological rescue of noise induced hearing loss using N-acetylcysteine and acetyl-L-carnitine.Hear Res, 2007, 226, (1- 2), 104-113. (Pubitemid 46428031)
256. Firuzi, O.; Asadollahi, M.; Gholami, M.; Javidnia, K., Composition and biological activities of essential oils from four Heracleum species.Food Chemistry 2010, 122, (1), 117-122.
257. Firuzi, O.; Javidnia, K.; Gholami, M.; Soltani, M.; Miri, R., Antioxidant activity and total phenolic content of 24 Lamiaceae species growing in Iran.Nat Prod Commun, 2010, 5, (2), 261-264.
258. Victor, V.M.; Apostolova, N.; Herance, R.; Hernandez-Mijares, A.; Rocha, M., Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria- targeted antioxidants as potential therapy.Curr Med Chem, 2009, 16, (35), 4654-4667.
259. Ramos-Marquez, M.E.; Siller-Lopez, F., Current antioxidant molecular therapies for oxidative stress-related ailments.Curr Gene Ther, 2008, 8, (4), 256-263.
260. Ristow, M.; Zarse, K.; Oberbach, A.; Kloting, N.; Birringer, M.; Kiehntopf, M.; Stumvoll, M.; Kahn, C.R.; Bluher, M., Antioxidants prevent healthpromoting effects of physical exercise in humans.Proc Natl Acad Sci U S A, 2009, 106, (21), 8665-8670.
261. Adabag, A.S.; Ishani, A.; Bloomfield, H.E.; Ngo, A.K.; Wilt, T.J., Efficacy of N-acetylcysteine in preventing renal injury after heart surgery: a systematic review of randomized trials.Eur Heart J, 2009, 30, (15), 1910-1917.
262. Baker, W.L.; Anglade, M.W.; Baker, E.L.; White, C.M.; Kluger, J.; Coleman, C.I., Use of N-acetylcysteine to reduce post-cardiothoracic surgery complications: a meta-analysis.Eur J Cardiothorac Surg, 2009, 35, (3), 521-527.
263. Nigwekar, S.U.; Kandula, P., N-acetylcysteine in cardiovascular- surgeryassociated renal failure: a meta-analysis.Ann Thorac Surg, 2009, 87, (1), 139-147.
264. Naughton, F.; Wijeysundera, D.; Karkouti, K.; Tait, G.; Beattie, W.S., Nacetylcysteine to reduce renal failure after cardiac surgery: a systematic review and meta-analysis.Can J Anaesth, 2008, 55, (12), 827-835.
265. Ho, K.M.; Morgan, D.J., Meta-analysis of N-acetylcysteine to prevent acute renal failure after major surgery.Am J Kidney Dis, 2009, 53, (1), 33-40.
266. Sutherland, E.R.; Crapo, J.D.; Bowler, R.P., N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease.COPD, 2006, 3, (4), 195-202. (Pubitemid 44949059)
267. Arain, M.A.; Abdul Qadeer, A., Systematic review on "vitamin E and prevention of colorectal cancer".Pak J Pharm Sci, 2010, 23, (2), 125-130.
268. Myung, S.K.; Kim, Y.; Ju, W.; Choi, H.J.; Bae, W.K., Effects of antioxidant supplements on cancer prevention: meta-analysis of randomized controlled trials.Ann Oncol, 2010, 21, (1), 166-179.
269. Bardia, A.; Tleyjeh, I.M.; Cerhan, J.R.; Sood, A.K.; Limburg, P.J.; Erwin, P.J.; Montori, V.M., Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and metaanalysis. Mayo Clin Proc, 2008, 83, (1), 23-34.
270. Alkhenizan, A.; Hafez, K., The role of vitamin E in the prevention of cancer: a meta-analysis of randomized controlled trials.Ann Saudi Med, 2007, 27, (6), 409-414. (Pubitemid 351234115)
271. Polyzos, N.P.; Mauri, D.; Tsappi, M.; Tzioras, S.; Kamposioras, K.; Cortinovis, I.; Casazza, G., Combined vitamin C and E supplementation during pregnancy for preeclampsia prevention: a systematic review.Obstet Gynecol Surv, 2007, 62, (3), 202-206. (Pubitemid 46294789)